Last reviewed · How we verify
Ferric polymaltose hydroxide complex IM
Ferric polymaltose hydroxide complex IM is a marketed iron replacement therapy developed by CN NGANOU-GNINDJIO, MD, MSc. The key composition patent expires in 2028, providing a period of exclusivity that supports market positioning. The primary risk is the lack of disclosed revenue and key trial results, which may limit investor confidence and competitive insights.
At a glance
| Generic name | Ferric polymaltose hydroxide complex IM |
|---|---|
| Also known as | Iron polymaltose hydroxide complex IM |
| Sponsor | CN NGANOU-GNINDJIO, MD, MSc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: